Bullish
FibroBiologics begins dosing patients in diabetic ulcer trial By Investing.com
FibroBiologics has initiated its Phase 1/2 clinical trial for CYWC628, an allogeneic fibroblast-spheroid cell-based therapy, to treat diabetic foot ul...